The Latest Breaking News from FDA

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

The CDC and FDA, when confronted with scarce vaccine supply, refuse to learn from their COVID-19 mistakes.

The administration declares monkeypox a public health emergency and says it will make it easier to get vaccines to patients.

Plus: Schools surveilling students online, Tim Wu leaving the White House, and more...

Here's a roundup of top developments in the biotech space over the last 24 hours:

The cigarette is the only legal consumer product that – when used as intended – causes the premature death of half of long-term users.

Alternate monkeypox treatment caught in regulatory delays

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

Here's a roundup of top developments in the biotech space over the last 24 hours:

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.